Three burn­ing 2024 ques­tions for Pfiz­er: What to do in weight loss, the hunt for megablock­busters, and in­te­grat­ing the deals

Pfiz­er has de­clared 2024 to be a year of ex­e­cu­tion. It’s like­ly to be judged on whether it can al­so be a year when the stock turned around, and in­vestors turned in­to be­liev­ers of its post-Covid strat­e­gy.

On Tues­day, the com­pa­ny an­nounced fi­nan­cial re­sults for the fi­nal quar­ter of 2023. It’s em­braced cost cuts, im­proved the bal­ance sheet and in­te­grat­ed the com­pa­nies they ac­quired us­ing the prof­its that were gen­er­at­ed through their (now in de­cline) Covid prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER